Full Text PA-96-071 DNA DAMAGE AND REPAIR IN CENTRAL NERVOUS SYSTEM INJURY NIH GUIDE, Volume 25, Number 29, August 30, 1996 PA NUMBER: PA-96-071 P.T. 34 Keywords: Nervous System Injury Wound Healing National Institute of Neurological Disorders and Stroke PURPOSE The National Institute of Neurological Disorders and Stroke (NINDS), invites applications for support of research that will increase our knowledge of the genetic, molecular, cellular, and physiological mechanisms of DNA injury and repair mechanisms in the nervous system after ischemic and traumatic injury, and in neurodegenerative disorders. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This PA, DNA Damage and Repair in CNS Injury, is related to the priority areas of heart disease and stroke and unintentional injuries. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0 or Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-512-1800). ELIGIBILITY REQUIREMENTS Applications may be submitted by domestic and foreign institutions, for-profit and non-profit organizations, public or private, such as universities, colleges, hospitals, laboratories, units of State and local governments, and eligible agencies of the Federal government. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards and program project (P01) grants. Applications from minority institutions, minority individuals, and women are particularly encouraged. MECHANISM OF SUPPORT The mechanisms of support for grants in this area will be the investigator-initiated research project grant (R01), FIRST (R29) award, and program project grant (P01). The principal investigator will plan, direct, and, along with any co-investigators, perform the research. Applicants planning to submit a new (Type 1) investigator-initiated grant application requesting $500,000 or more in direct costs for any year must contact NINDS program staff before submitting the application. A cover letter that identifies the program staff member who agrees to accept the assigned application must be sent with the application. RESEARCH OBJECTIVES Background: The basis of current knowledge and concepts of DNA damage and repair are largely derived from non-neuronal cells/tissues and non-mammalian research. Therefore, a significant gap of knowledge exists concerning the fundamental biochemical processes that may lead to DNA damage and repair in the brain, and the physiological relevance of such processes. There is evidence of DNA damage in experimental stroke and trauma, and neurodegenerative processes have been attributed to impairment in DNA repair mechanisms. Thus, DNA damage is a likely factor in promoting CNS pathophysiology, and DNA repair may be an important mechanism for maintenance of normal physiological function. DNA damage and repair are vibrant areas of research with broad implications for understanding pathology in human disease and injury. The application of the science of DNA injury and repair may yield new and important information on mechanisms of neuronal damage, and provide opportunities for the development of novel and effective therapies to reduce CNS injury in stroke, trauma, and neurodegenerative disorders. The NINDS supports many basic and applied science programs focused on understanding the biology of neurons and glia. It is anticipated that further progress in basic neurobiology will provide insight into the inordinately complex molecular and cellular processes involved in CNS ischemic and traumatic injury and repair. Therefore, the intent of this announcement is to encourage investigator-initiated applications to study the mechanisms of DNA damage and repair in cerebral ischemia and CNS trauma. Research Goals and Scope: Examples of investigator-initiated research grant applications for basic, applied, and clinical studies related to the understanding of DNA damage and repair mechanisms in the CNS, may include, but should not necessarily be limited to: o Investigate the mechanisms of DNA damage and repair in neurons, since our knowledge base, thus far, has been largely derived from non-neuronal tissue (dividing cells); o Clarify the causal relationships between DNA damage and pathological CNS responses to stroke and CNS trauma and neurodegenerative disorders; o Explore the role of ICE, Bcl-2, p53, DNA pol b, bax and related genes and gene families in DNA damage and repair in CNS injury and neurodegenerative disorders; o Define critical events in pathological cascades resulting from DNA damage such as trigger points or points at which reversible and irreversible damage occurs; o Identify genomic locations of DNA damage and repair in neurons for an accurate assessment of the biological importance of these lesions; o Assess the differences between potentially deficient transcription-coupled repair and global repair mechanisms in selective regions after CNS injury; o Identify genes, enzymes, and receptors associated with DNA repair in neurons; o Assess the effects of DNA injury on the expression of trophic factors involved in either development or regeneration after CNS injury; o Identify the contribution of extracellular (e.g. NMDA, NO, pH, Ca++) and intracellular (e.g. mitochondrial dysfunction, deacylation of phospholipids) mechanisms to DNA damage and apoptosis in neurons; o Investigate the role of DNA injury and repair as mechanisms underlying selective vulnerability, penumbra, pre-conditioning, delayed cell death, and reperfusion injury in the CNS; o Examine the role of the DNA repair enzymes in cerebral injury from stroke and trauma using transgenic animals with various defects of nucleotide excision repair; o Assess the extent to which DNA damage and defective repair in utero may compromise normal fetal development of the CNS; o Investigate the role of DNA repair mechanisms and responses of the cerebral blood vessel wall cells following CNS ischemia and trauma. Cerebrovascular responses are virtually unexplored and could provide insight into the role of angiogenesis in CNS cell and tissue survival; o Identify methods to measure DNA damage non-invasively in the brain (e.g., SPECT, MRI). Applicants are encouraged to develop and use new or refined methodologies, instrumentation, and procedures that will reveal mechanistic details of the CNS injury and reparative processes. Basic, applied, or clinical studies to improve DNA damage and repair control, prevent molecular pathophysiological changes, or restrain cell death are welcome. INCLUSION OF WOMEN AND MINORITIES IN RESEARCH INVOLVING HUMAN SUBJECTS It is the policy of the NIH that women and members of minority groups and their subpopulations must be included in all NIH supported biomedical and behavioral research projects involving human subjects, unless a clear and compelling rationale and justification is provided that inclusion is inappropriate with respect to the health of the subjects or the purpose of the research. This new policy results from the NIH Revitalization Act of 1993 (Section 492B of Public Law 103-43) and supersedes and strengthens the previous policies (Concerning the Inclusion of Women in Study Populations, and Concerning the Inclusion of Minorities in Study Populations), which have been in effect since 1990. The new policy contains some provisions that are substantially different from the 1990 policies. All investigators proposing research involving human subjects should read the "NIH Guidelines For Inclusion of Women and Minorities as Subjects in Clinical Research," which have been published in the Federal Register of March 28, 1994 (FR 59 14508-14513) and reprinted in the NIH Guide for Grants and Contracts, Volume 23, Number 11, March 18, 1994. Investigators also may obtain copies of the policy from the program staff listed under INQUIRIES. Program staff may also provide additional relevant information concerning the policy. APPLICATION PROCEDURES Applications are to be submitted on the grant application form PHS 398 (rev. 5/95) according to the instructions included in the application package. Applications kits are available at most institutional offices of sponsored research and may be obtained from the Grants Information Office, Office of Extramural Outreach and Information Resources, National Institutes of Health, 6701 Rockledge Drive, MSC 7910, Bethesda, MD 20892-7910, telephone 301/710-0267, email: ASKNIH@odrockm1.od.nih.gov. The title and number of the program announcement must be typed in Section 2 on the face page of the application. The completed original application and five legible copies must be sent or delivered to: DIVISION OF RESEARCH GRANTS NATIONAL INSTITUTES OF HEALTH 6701 ROCKLEDGE DRIVE ROOM 1040 MSC 7710 BETHESDA MD 20892-7710 BETHESDA MD 20817 (for courier service) A number of other Institutes, Centers and Divisions (ICD) at the NIH may be interested in the general subject of this program announcement. For example, the NINDS and the NIA have mutual interest in understanding chronic neurodegenerative disorders such as Alzheimer's Disease. Applications submitted in response to this PA that propose to do research in scientific areas that overlap ICD interests will receive a funding component assignment in accord with existing referral guidelines and procedures established by the Division of Research Grants, NIH. REVIEW CONSIDERATIONS Applications that are complete will be evaluated for scientific and technical merit by an appropriate peer review group convened in accordance with the standard NIH peer review procedures. As part of the initial merit review, all applications will receive a written critique and undergo a process in which only those applications deemed to have the highest scientific merit, generally the top half of applications under review, will be discussed, assigned a priority score, and receive a second level review by the appropriate national advisory council or board. Review Criteria o scientific, technical, or medical significance and originality of proposed research; o appropriateness and adequacy of the experimental approach and methodology proposed to carry out the research; o qualifications and research experience of the Principal Investigator and staff, particularly, but not exclusively, in the area of the proposed research; o availability of the resources necessary to perform the research; o appropriateness of the proposed budget and duration in relation to the proposed research; o adequacy of plans to include both genders and minorities and their subgroups as appropriate for the scientific goals of the research. Plans for the recruitment and retention of subjects will also be evaluated. The initial review group will also examine the provisions for the protection of human and animal subjects and the safety of the research environment. AWARD CRITERIA The standard review criteria will be used to assess the scientific merit of applications. Applications will compete for available funds with all other applications. The following will be considered when making funding decisions: o quality of the proposed projects as determined by peer review; o availability of funds; and o program balance among research areas. INQUIRIES Inquiries are encouraged. The opportunity to clarify any issues or questions from potential applicants is welcome. Dr. Thomas P. Jacobs Division of Stroke and Trauma National Institute of Neurological Disorders and Stroke Federal Building, Room 8A13 Bethesda, MD 20892 Telephone: (301) 496-4226 FAX: (301) 480-1080 Email: TJ12G@NIH.GOV Dr. Mary Ellen Cheung Division of Stroke and Trauma National Institute of Neurological Disorders and Stroke Federal Building, Room 8A13 Bethesda, MD 20892 Telephone: (301) 496-4226 FAX: (301) 480-1080 Email: MM108W@NIH.GOV Direct inquiries regarding fiscal matters to: Ms. Kathleen Howe Division of Extramural Activities National Institute of Neurological Disorders and Stroke Federal Building, Room 1004 Bethesda, MD 20892 Telephone: (301) 496-9231 FAX: (301) 402-0219 Email: KH52X@NIH.GOV AUTHORITY AND REGULATIONS This program is described in the Catalogue of Federal Domestic Assistance, Number 93.853, Clinical Research Related to Neurological Disorders, and 93.854, Biological Basis Research in the Neurosciences. Grants will be awarded under the authority of the Public Health Service Act, Title IV, Section 301 (Public Law 78-410, as amended: 42 USC 241) and administered under PHS grant policies and Federal Regulations 42 CFR Part 52 and 45 CFR 74. This program is not subject to Health Services Agency Review of the intergovernmental review requirements of Executive Order 12372. The PHS strongly encourages all grant and contract recipients to provide a smoke-free workplace and promote the non-use of all tobacco products. In addition, Public Law 103-227, the Pro-Children Act of 1994, prohibits smoking in certain facilities (or in some cases, any portion of a facility) in which regular or routine education, library, day care, health care or early childhood development services are provided to children. This is consistent with the PHS mission to protect and advance the physical and mental health of the American people. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |